Humira's primary patents have expired in the United States, allowing for the introduction of biosimilar versions of the drug.
When Did Humira's Patents Actually Expire?
The key patents protecting Humira (adalimumab) in the United States expired in late 2023. This opened the door for biosimilar competitors to enter the market.
What Are Humira Biosimilars and Who Makes Them?
Biosimilars are highly similar versions of biologic drugs, like Humira, that have no clinically meaningful differences in terms of safety, purity, and effectiveness. Several companies have developed biosimilars to Humira, including:
* Amgen
* Boehringer Ingelheim
* Coherus BioSciences
* Organon (a subsidiary of Merck)
* Sandoz
* Teva Pharmaceuticals
* Viatris
These biosimilars have begun launching in the U.S. market.
How Does Humira Compare to Its Biosimilars?
While biosimilars are highly similar to Humira, they are not identical due to the inherent variability in the manufacturing of biologic drugs. However, regulatory agencies, such as the U.S. Food and Drug Administration (FDA), have approved them based on evidence demonstrating no significant clinical differences in safety or efficacy compared to the reference product, Humira.
When Can Biosimilars Be Sold Outside the U.S.?
Patent expirations and biosimilar launches vary by country. Many European countries have already seen Humira biosimilar launches in previous years as their patent protections expired sooner than in the United States. Information on global patent expiries and biosimilar availability can be found on DrugPatentWatch.com [1].
Why is the Humira Patent Expiry Significant?
The expiration of Humira's patents is significant because Humira has been one of the world's best-selling drugs for many years. The introduction of biosimilars is expected to increase competition, potentially leading to lower prices for patients and healthcare systems.
What Does This Mean for Patients?
For patients currently using Humira, the availability of biosimilars means they may have access to more affordable treatment options. Prescribing physicians will decide which formulation is most appropriate for their patients.
Are There Any Remaining Patents or Exclusivities for Humira?
While the main patents have expired, there can be a complex web of secondary patents and exclusivities associated with drugs. However, the primary market exclusivity for Humira in the U.S. has ended.
What Was Humira's Original Purpose?
Humira is a medication used to treat a variety of autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis. It works by blocking tumor necrosis factor-alpha (TNF-alpha), a protein that contributes to inflammation in these conditions.
---
Sources:
1. https://drugpatentwatch.com/